Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
36. |
ECCT/15/10/01 | VRC01 Monoclonal HIV Antibodies Study Safety and Virologic Effect Of A Human Monoclonal Antibody, VRC-HIVmAb060-00-Ab (VRCOl), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to Adults During Early Acute HIV Infection. |
Principal Investigator(s) 1. Josphat K Kosgei Site(s) in Kenya KEMRI Walter Reed Project Kericho |
View |
37. |
ECCT/15/11/04 | VAC040 A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months) |
Principal Investigator(s) 1. John Anthony Gerard Scott Site(s) in Kenya KEMRI-Wellcome Trust Research Program |
View |
38. |
ECCT/15/04/02 | Plasma concentration profiles after oral administration of oleylphosphocholine tablet formulation: safety, tolerability and pharmacokinetics of 100 mg single dose in healthy male volunteers. |
Principal Investigator(s) 1. Ravasco Rashid Juma Site(s) in Kenya KEMRI |
View |
39. |
ECCT/14/11/02 | A5297 An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3 |
Principal Investigator(s) 1. VICTOR AKELO Site(s) in Kenya KEMRI/CDC CLINICAL RESEARCH CENTRE |
View |
40. |
ECCT/14/11/01 | ZEBOV Trial A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya. |
Principal Investigator(s) 1. Philip Bejon 2. Patricia Njuguna Site(s) in Kenya KEMRI Wellcome Trust Research Programme |
View |